GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hill-Rom Holdings Inc (NYSE:HRC) » Definitions » Debt-to-EBITDA

Hill-Rom Holdings (Hill-Rom Holdings) Debt-to-EBITDA : 4.04 (As of Sep. 2021)


View and export this data going back to 1989. Start your Free Trial

What is Hill-Rom Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hill-Rom Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $236 Mil. Hill-Rom Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $1,825 Mil. Hill-Rom Holdings's annualized EBITDA for the quarter that ended in Sep. 2021 was $510 Mil. Hill-Rom Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2021 was 4.04.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Hill-Rom Holdings's Debt-to-EBITDA or its related term are showing as below:

HRC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.14   Med: 3.88   Max: 11.07
Current: 3.72

During the past 13 years, the highest Debt-to-EBITDA Ratio of Hill-Rom Holdings was 11.07. The lowest was 1.14. And the median was 3.88.

HRC's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.235 vs HRC: 3.72

Hill-Rom Holdings Debt-to-EBITDA Historical Data

The historical data trend for Hill-Rom Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hill-Rom Holdings Debt-to-EBITDA Chart

Hill-Rom Holdings Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.86 4.04 4.96 3.58 3.72

Hill-Rom Holdings Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.06 3.49 2.55 3.51 4.04

Competitive Comparison of Hill-Rom Holdings's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Hill-Rom Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hill-Rom Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hill-Rom Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hill-Rom Holdings's Debt-to-EBITDA falls into.



Hill-Rom Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hill-Rom Holdings's Debt-to-EBITDA for the fiscal year that ended in Sep. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(235.7 + 1825.2) / 554.2
=3.72

Hill-Rom Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(235.7 + 1825.2) / 510.4
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2021) EBITDA data.


Hill-Rom Holdings  (NYSE:HRC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Hill-Rom Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hill-Rom Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hill-Rom Holdings (Hill-Rom Holdings) Business Description

Traded in Other Exchanges
N/A
Address
130 East Randolph Street, Suite 1000, Chicago, IL, USA, 60601
Hill-Rom Holdings Inc is a global provider of hospital equipment and medical supplies, including hospital beds for high- and low-acuity settings. Hill-Rom reports financial data across three operating segments: patient support systems (50% of fiscal 2018 sales), front-line care (34%), and surgical solutions (16%). The firm has significant operations internationally, with roughly 30% of revenue derived from international sources and the remaining 70% from its U.S. business.
Executives
Mary Kay Ladone officer: SVP, Corp. Dev., Strat. & IR 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Deborah Rasin officer: SVP, Chief Legal Officer TWO PRUDENTIAL PLAZA, SUITE 4100, CHICAGO IL 60601
Paul Sherwood Johnson officer: SVP & Pres. - PSS Acute Care TWO PRUDENTIAL PLAZA 180 NORTH STETSON AVENUE, SUITE 4100 CHICAGO IL 60601
Andreas G Frank officer: SVP, Pres. Front Line Care C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Richard M Wagner officer: Corporate Controller 221 WEST PHILADELPHIA STREET, SUITE 60W, YORK PA 17401-2991
Amy M. Dodrill officer: President - Surgical Solutions 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Gary Lee Ellis director THE TORO COMPANY, 8111 LYNDALE AVENUE SOUTH, BLOOMINGTON MN 55420
Mary Garrett director ETHAN ALLEN DRIVE, DANBURY CT 06811
Gregory J. Moore director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
William Kucheman director C/O DAN DUGAN, FINANCIAL PERSPECTIVES, 3025 HARBOR LN., SUITE 200, PLYMOUTH MN 55447
James R Giertz director
Ronald A Malone director 3 HUNTINGTON QUADRANGLE, SUITE 200S, MELVILLE NY 11747
Felicia F Norwood director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
William G Dempsey director C/O LANDAUER, INC., 2 SCIENCE ROAD, GLENWOOD IL 60425
Nancy M Schlichting director 200 WILMOT ROAD, DEERFIELD IL 60015